<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924414</url>
  </required_header>
  <id_info>
    <org_study_id>20180456</org_study_id>
    <secondary_id>1R01AG059417-01A1</secondary_id>
    <nct_id>NCT03924414</nct_id>
  </id_info>
  <brief_title>Trial of Parkinson's And Zoledronic Acid</brief_title>
  <acronym>TOPAZ</acronym>
  <official_title>TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parkinson's Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>California Pacific Medical Center Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of
      zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and
      older with Parkinson's disease and parkinsonism with 2 years of follow-up. A total of 3500
      participants will be enrolled and randomized in the United States. Participants, follow-up
      outcome assessors, and study investigators will be blinded to assigned study treatment. This
      trial is funded by the National Institute of Aging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This home-based randomized clinical trial is designed to test the efficacy of ZA-5 mg in
      Parkinson's disease (PD) and parkinsonism patients. This trial will also address barriers to
      treatment of patients with PD and parkinsonism by providing rigorous evidence about whether
      ZA reduces fracture risk in patients with PD and parkinsonism, simplifying treatment by
      giving ZA at home without extra medical visits and BMD testing, and overcoming poor
      persistence with oral therapies because one infusion may prevent bone loss for at least 2
      years. The outcome of this trial will demonstrate how a home-based fracture prevention can
      reach older PD patients who would not otherwise receive treatment to reduce their high risk
      of fractures.

      Patients with PD will be recruited throughout the US by participating neurologists and health
      networks as well as the Parkinson's Foundation. Patients may also self-refer to the study.
      Interested patients can access study information on a study website
      (topaz.eurekaplatform.org) as well as through the Parkinson's Foundation Helpline. Patients
      who wish to enroll will be directed to an interactive electronic consent (eConsent).
      Following eConsent, participants complete a screening questionnaire (to confirm eligibility),
      followed by a baseline questionnaire. If a participant is determined to be eligible following
      these steps, they may be scheduled for a Telemedicine assessment to further confirm the PD or
      parkinsonism diagnosis, unless they have been referred directly from a participating
      neurologist. If confirmed, the participant will be mailed a supply of vitamin D3 800-1000 IU
      and instructed to take one vitamin D tablet every day for 2 months. Lastly, a Nurse Home
      Visit will be scheduled and conducted to confirm final eligibility, randomization, and
      administration of the study drug, if appropriate. Participants who are randomized will be
      contacted every 4 months for at least 2 years to determine if they have had any fractures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">November 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and older with Parkinson's Disease with at least 2 years of follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Clinical Fractures</measure>
    <time_frame>2 years</time_frame>
    <description>All clinical fractures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Hip Fractures</measure>
    <time_frame>2 years</time_frame>
    <description>Hip fractures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Osteoporosis</condition>
  <condition>Parkinsonism</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid (ZA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single intravenous infusion of Zoledronic acid (5 mg) infused over 45 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single intravenous infusion of placebo infused over 45 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid 5Mg/Bag 100Ml Inj</intervention_name>
    <description>Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.</description>
    <arm_group_label>Zoledronic acid (ZA)</arm_group_label>
    <other_name>Reclast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline 100 ml (placebo) IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women age 65 years or older

          -  Current Parkinson's Disease diagnosis or neurodegenerative parkinsonism diagnosis
             (including progressive supranuclear palsy, multiple system atrophy, cortical basal
             degeneration, vascular parkinsonism, dementia with Lewy bodies or another form of
             neurodegenerative parkinsonism) based on an expert assessment (neurologist diagnosis
             via medical records confirmation or Telemedicine Screening Assessment)

          -  Willing and able to continue in follow-up for at least 2 years

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  History of hip fracture

          -  Any use of a bisphosphonate drug within the last 12 months

          -  Use of any other osteoporosis treatment (such as SERMs and denosumab) within the last
             6 months

          -  Tooth extraction or invasive dental procedures within the past 30 days or
             planned/scheduled extraction/procedure in the next 12 months

          -  Non-ambulatory, i.e., unable to walk without assistance of another person.

          -  Undergoing kidney dialysis

          -  A diagnosis of multiple myeloma or Paget's disease

          -  Unable to speak or read English sufficiently to complete informed consent

          -  Any other criteria, which would make the patient unsuitable to participate in this
             study as determined by the study staff (e.g., an uncontrolled drug and/or alcohol
             addiction)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Cummings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CPMC Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana R Kriesel, MPH, MS</last_name>
    <phone>(877) 378-6729</phone>
    <email>robertdc@sutterhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher P Schambach, MA</last_name>
    <phone>(877) 378-6729</phone>
    <email>schambcp@sutterhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Parkinson Clinic</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neng Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
    <investigator>
      <last_name>Caroline Tanner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook County Health &amp; Hospitals System</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Glen Cove</city>
        <state>New York</state>
        <zip>11542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
    <investigator>
      <last_name>Kenneth W Lyles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mustafa Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veracity Neuroscience LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
    <investigator>
      <last_name>Mark LeDoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>800-473-4636</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Shannon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>Neurology</keyword>
  <keyword>Bone</keyword>
  <keyword>Fracture</keyword>
  <keyword>Parkinsonism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

